Replies to post #64367 on Biotech Values

[DewDiligence]

MNTA TEVA WPI SNY: Lovenox patent update:

The appellate court has given Amphastar and Teva until 8/21/08 to respond to Sanofi’s request for an en banc rehearing that was filed in July.

Amphastar’s 180-day exclusivity clock on generic Lovenox cannot start until the court either: i) conducts the rehearing and rules on it; or ii) denies the request for a rehearing.

As a result of the court schedule, Sandoz/MNTA no longer expect a Lovenox launch during 2008. (I noted this last week in #msg-30763224.)